Review of Experimental Compounds Demonstrating Anti-Toxoplasma Activity

Authors

Madalyn M. McFarland, University of Nebraska at OmahaFollow
Sydney J. Zach, University of Nebraska at Omaha
Xiaofang Wang, The University of Nebraska Medical CenterFollow
Lakshmi-Prasad Potluri, University of Nebraska at Omaha
Andrew J. Neville, University of Nebraska at OmahaFollow
Jonathan L. Vennerstrom, University of Nebraska Medical CenterFollow
Paul H. Davis, University of Nebraska at OmahaFollow

Document Type

Article

Publication Date

9-6-2016

Publication Title

Antimicrob Agents Chemother

Volume

60

First Page

7017

Last Page

7034

Abstract

Toxoplasma gondii is a ubiquitous apicomplexan parasite capable of infecting humans and other animals. Current treatment options for T. gondii infection are limited and most have drawbacks, including high toxicity and low tolerability. Additionally, no FDA-approved treatments are available for pregnant women, a high-risk population due to transplacental infection. Therefore, the development of novel treatment options is needed. To aid this effort, this review highlights experimental compounds that, at a minimum, demonstrate inhibition of in vitro growth of T. gondii. When available, host cell toxicity and in vivo data are also discussed. The purpose of this review is to facilitate additional development of anti-Toxoplasma compounds and potentially to extend our knowledge of the parasite.

Comments

Supplemental material for this article may be found at http://dx.doi.org/10.1128 /AAC.01176-16. Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Recommended Citation

McFarland MM, Zach SJ, Wang X, Potluri L-P, Neville AJ, Vennerstrom JL, Davis PH. 2016. Review of experimental compounds demonstrating antiToxoplasma activity. Antimicrob Agents Chemother 60:7017–7034. doi:10.1128/AAC.01176-16.